Clinical Trials Directory

Trials / Completed

CompletedNCT05313984

OptiLUTS Part C: the Development of a Symptom Assessment Tool in Sacral Neuromodulation.

Optimization of Therapy Resistant LUTS (OptiLUTS) Part C: the Development of a Symptom Assessment Tool in Sacral Neuromodulation: a Prospective Single Centre Study.

Status
Completed
Phase
Study type
Observational
Enrollment
93 (actual)
Sponsor
University Hospital, Ghent · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Sacral neuromodulation (SNM) is a two-staged 2nd-line therapy for therapy-resistant LUTS and fecal incontinence. Currently, the assessment of symptoms at baseline and after stage I is directed towards a discipline related evaluation. The OptiLUTS trial strives for a more holistic approach, taking all pelvic floor dysfunctions into account. A holistic assessment tool will be developed and SNM-care pathway will be set-up.

Detailed description

A prospective single centre trial is set up. Patients planned for the two-staged tined lead procedure are enrolled. Bladder and bowel diaries and patient reported outcome measures (PROMS) will be collected at baseline and in between stage I and stage II, and PROMS at one month, 6 months and 12 months after definitive implant. Phase I Step 1: The current implant rate, true success rate, outcomes and false positive rate will be measured. Step 2: Development of a holistic symptom assessment tool. Phase II Implementation of the SNM care pathway.

Conditions

Interventions

TypeNameDescription
DEVICESacral neuromodulationSacral neuromodulation: the 2-staged tined lead procedure. (Interstim II therapy, Medtronic). Stage I: Placement of a tined-lead electrode. 2 - 4 weeks test phase. Stage II: Placement of an implantable pulse generator.

Timeline

Start date
2018-03-01
Primary completion
2021-12-01
Completion
2021-12-31
First posted
2022-04-06
Last updated
2024-09-19

Locations

1 site across 1 country: Belgium

Source: ClinicalTrials.gov record NCT05313984. Inclusion in this directory is not an endorsement.